key: cord-0954859-8m2fnd09
authors: Sran, Kiran; Breen, Cormac; Ho, Garm Chi; Douthwaite, Samuel T.; Calder, Francis; Game, David S.; Olsburgh, Jonathon
title: Navigating COVID-19 in Renal Transplantation: From “Alpha” to “Omicron”; A Single-center Experience
date: 2022-03-24
journal: Transplantation
DOI: 10.1097/tp.0000000000004125
sha: a5445ec5bb61867d5f1bc9da5b6654d297028549
doc_id: 954859
cord_uid: 8m2fnd09

nan

T wo years on from its onset, COVID-19 continues to present challenges for end-stage kidney disease patients and kidney transplant recipients. Novel variants of the SARS-CoV-2 virus have emerged and rapidly gained dominance, the most recent being Omicron (B.1.1.529), first identified in the United Kingdom on November 27, 2021.

In the general population, Omicron has demonstrated high infectivity, but with lower hospitalization and intensive care unit admissions compared with previous variants. 1 However, outcomes following infection in kidney transplant recipients remain uncertain, particularly in the early posttransplant period when immunosuppression is maximal. There is increasing evidence that Omicron infection may evade immunity conferred from previous SARS-CoV-2 infection and vaccination. 1 In previous COVID-19 surges, we encountered only a single case of nosocomial transmission of SARS-CoV-2 in a recently transplanted patient. With the emergence of Omicron, we were keen to review its impact on clinical outcomes in this cohort. To date, we are not aware of other reports of SARS-CoV-2 infection with Omicron genotype in the early posttransplant setting. We present 5 transplant recipients (out of 19 transplanted between December 15, 2021, and January 14, 2022) with Omicron infection in the first 10 d following transplantation.

The cases are summarized in Table 1 . Organ donors were confirmed to be negative for SARS-CoV-2 RNA by reverse transcriptase-polymerase chain reaction. Patients reported minimal or no symptoms relating to COVID-19 infection, with oxygen therapy for fluid overload indicated in only 1.

No COVID-19-related mortality or requirement of ventilatory support was seen. In contrast with previous experience, the clinical course of these patients is encouraging.

Over the course of the pandemic, the management of transplant recipients with COVID-19 has evolved based on studies in the general population. In line with evidence demonstrating a significant benefit in unvaccinated nonhospitalized patients, sotrovimab was recommended against Omicron for the treatment of patients with mild to moderate COVID-19 and at least 1 risk factor of developing severe disease. 2,3 Therefore, transplant recipients in the hospital for non-COVID-19 reasons were deemed eligible for sotrovimab therapy within 5 d of a positive SARS-CoV-2 reverse transcriptase-polymerase chain reaction. 3 Vaccination appears to confer variable protection against COVID-19; however, even when initially effective, vaccineinduced protection wanes over time. 4 Many patient groups develop a less robust response to vaccination despite an enhanced schedule, 5 and this mirrors the findings in patients with functioning transplants. 6 Neither testing for T-cell immunity nor measurement of antibody levels has been routinely available. Although patients may enter their incident transplantation episode with reduced protection against COVID-19 infection, with the range of adjunctive treatments currently available, this may not have a significant adverse effect on immediate outcomes.

Before the appearance of Omicron, the combination of vaccination and protective measures aided control of transmission to incident transplant patients. None of our patients were aware of having had previous SARS-CoV-2, and our single unvaccinated patient did not have SARS-CoV-2 S1/S2 immunoglobulin G (IgG). The remaining 4 patients, all vaccinated with varying regimens, had detectable SARS-CoV-2 S1/S2 IgG levels. Four of our 5 patients received sotrivimab. The development of Omicron, the presence of SARS-CoV-2 S1/S2 IgG levels and availability of monoclonal therapies are all possible combinatory contributing factors to the mild clinical picture observed.

The goal of preventing infection, through lockdown and isolation measures, partially achievable in previous waves of the pandemic, has not been sustainable with Omicron. Omicron, particularly in the face of SARS-CoV-2 S1/ S2 IgG and newly available treatments, may result in 

Report 50 -hospitalisation risk for Omicron cases in England

COMET-ICE Investigators. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab

Interim clinical commissioning policy: neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19

Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study

Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity -the OCTAVE trial. Preprints with The Lancet

NHSBT Organ and Tissue Donation and Transplantation Clinical Team. Real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against SARS-CoV-2 in solid organ and islet transplant recipients